zolpidem

Quick answers

What is zolpidem?

Zolpidem (brand Ambien; Ambien CR) is a non-benzodiazepine hypnotic (“Z-drug”) approved for insomnia. It is often considered when rapid sleep onset is the primary target symptom.

What is AMBIEN?

AMBIEN is a brand name for zolpidem (other brands: AMBIEN CR).

What is AMBIEN (zolpidem) used for?

Label indications include: Insomnia (label).

What drug class is AMBIEN (zolpidem)?

Non-Benzo Hypnotic.

What is the mechanism of action of AMBIEN (zolpidem)?

Non-benzodiazepine hypnotic (“Z-drug”); GABA-A receptor positive allosteric modulator.

What strengths does AMBIEN (zolpidem) come in?

Immediate-release tablets: 5 mg, 10 mg.

General information

Treat zolpidem as a time-limited adjunct alongside CBT-I and sleep hygiene; avoid chronic, open-ended refills. Use short prescriptions, define a stop plan, and discontinue if complex sleep behaviors or unsafe next-day impairment emerge.

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

• GABA-A receptor facilitation (non-benzodiazepine hypnotic class).

Metabolism & pharmacokinetics

• Rapid absorption; food delays onset and reduces peak exposure (label).
• Mean elimination half-life ~2.5 hours (range ~1.4–4.5 hours) in healthy adults (label).
• Converted to inactive metabolites eliminated primarily by renal excretion; CYP3A4 interactions can be clinically relevant.
• Exposure increases in older adults and hepatic impairment, increasing next-day impairment and fall risk; use the lowest effective dose and reassess safety after initiation or dose changes.

Dosing & administration

• Take immediately before bedtime, only when able to remain in bed for a full night.
• Food (especially high-fat meals) can delay onset; when rapid sleep onset is the goal, avoid taking with or immediately after a heavy meal.
• Use the lowest effective dose; avoid dose escalation when insomnia is driven by untreated mood symptoms, substances, pain, or sleep apnea.
• Avoid dosing after alcohol or other sedatives; reassess frequently and avoid open-ended refills.
• Avoid “middle of the night” redosing; if awakenings persist, reassess the diagnosis and consider alternatives rather than increasing hypnotic burden.

Monitoring & labs

• Assess next-day impairment (driving, work, falls) after initiation and dose changes; lower the dose or stop if safety is compromised.
• Screen for complex sleep behaviors and discontinue immediately if they occur.
• Reassess for untreated sleep apnea, substance use, and mood episodes when insomnia persists rather than escalating hypnotics.
• If continued beyond a brief course, plan taper attempts and reinforce CBT-I to reduce rebound insomnia.

Sources: FDA/DailyMed label; AASM insomnia guideline; evidence reviews.

Adverse effects

Interactions

• Avoid alcohol and other CNS depressants (opioids, benzodiazepines, sedating antipsychotics).
• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) can increase exposure; inducers (e.g., rifampin, St. John’s wort) can reduce efficacy—reassess sedation and response when interacting drugs change.
• Avoid combining with other sedative-hypnotics when possible; if combinations are unavoidable, start lower and increase follow-up frequency to reduce falls and driving risk.

Other useful information

• Favor CBT-I and sleep hygiene first; use zolpidem for short, clearly bounded courses with stop plans.
• Avoid in untreated sleep apnea or when nighttime wandering is a safety concern.
• If insomnia is chronic, treat underlying drivers rather than escalating hypnotic doses.
• Use short prescriptions with planned follow-up; discontinue if complex sleep behaviors, next-day impairment, or unsafe nighttime behaviors occur.

References